Monte Eaves’ a Kauffman Success Story

Monte Eaves is a professor of surgery at Emory University and Medical Director at Emory Aesthetic Center. He is also the man behind EMRGE, a company developing products that are revolutionizing the wound closure industry. EMRGE challenges the traditional needle and thread wound closure procedure with noninvasive and cost-effective technology that promotes healing and minimizes scarring. For this, Eaves was recently awarded the Office of Technology Transfer (OTT) award for 2017 Startup of The Year, one of many achievements. Shortly after, we got to talk with him about how he got there and the role OTT and Emory’s Kauffman Foundation Read More …

What Does Mixing Math, Physics, Computers, and Imagination Give You? A Pioneer in Radiation Oncology.

Ian R. Crocker, MD, FACR, is a radiation oncologist specializing in brain and eye tumors, who worked at Winship Cancer Institute for over 30 years. Throughout his career, Crocker was an active member of multiple innovation and research teams that sought to develop new medical technologies and methods to improve treatment outcomes and patient care. Some of his most notable successes include his co-invention of the BetaCath system to prevent the re-narrowing of arteries after an angioplasty and his involvement in the Emory start-up, Velocity Medical Solutions, which produced new, widely used imaging software to improve cancer treatment. Now retired Read More …

Lessons from Baseball: Applying Passion and Competitive Drive to Radiation Oncology

Tim Fox worked at Emory University as an Associate Professor & Director of Medical Physics from 1994 to 2014. In 2005 he and three of his Emory colleagues created the Emory start-up, Velocity Medical Solutions, which built and sold a multimodal medical imaging software. Velocity was later acquired by Varian Medical Systems and in 2014, Fox left Emory to accept a full-time position as the Associate Vice President of Imaging Informatics at Varian. Fox grew up playing baseball and now applies that same passion and drive to his entrepreneurial endeavors Just like the famous line from the baseball movie, Field Read More …

Treating Anxiety Disorders: Balancing the Real World and the Virtual World

Barbara Olasov Rothbaum, PhD, is the Associate Vice Chair of Clinical Research in Emory School of Medicine’s Department of Psychiatry, a professor in the Department of Psychiatry and Behavioral Science, and director of Emory’s Veterans Program and Emory’s Trauma & Anxiety Recovery Program. Dr. Rothbaum specializes in treatment of anxiety disorders, with a focus on Post-Traumatic Stress Disorder (PTSD). With over 200 scientific publications, Rothbaum has changed the field of PTSD and was a forerunner in the use of virtual reality in treatment of anxiety disorders. What initially drew you to the field of psychiatry? I went to UNC-Chapel Hill Read More …

Inventor Becomes Patient: My Tool Was Like a Trusted Friend Telling Me What Was Wrong

Ernest V. Garcia, PhD, or better known as Ernie, is an endowed professor in cardiac imaging and the director of Emory’s Nuclear Cardiology R&D Laboratory. He specializes in medical imaging and bioinformatics, particularly quantitative analysis of cardiac images. Ernie has received numerous awards and honors but to highlight a few he was named a Medical Imaging Industry Top 10 Nuclear Medicine Researcher by the Medical Imaging Magazine and was named to the Council of Distinguished Investigators of the Academy of Radiology Research. What lead you to pursue cardiac imaging as part of your profession? I was trained as a scientist, Read More …

It Started in My Basement, Now it Improves Patients Lives

Charles M. Epstein, MD, or “Chip” as he’s been known since childhood, is a professor of neurology specializing in epilepsy and the founder of  the Laboratory for Transcranial Magnetic Stimulation (TMS). He is also a co-inventor for the technology that is utilized by Emory partner Neuronetics, Inc in their NeuroStar TMS Therapy® for treating depression. Neuronetics has safely administered more than 10,000 NeuroStar TMS Therapy® treatments with clinically significant results: among patients studied, 54 percent responded to the therapy and 33 percent found their depression in remission. Neurostar wasn’t the first technology you were involved with. Could you tell us Read More …